

FIG.1

RESPONDER CELLS: RAT SPLEEN CELLS
STIMULATOR CELLS: HUMAN HEPATOCYTES

SPLEEN(S): SPLEEN CELLS FROM RATS TREATED WITH SALINE WHEN THEY WERE FETUSES.

HEP: IRRADIATED HUMAN HEPATOCYES.

SPLEEN(IU): SPLEEN CELLS FROM RATS TOLERIZED BY INTRAUTERINE INJECTION OF HUMAN HEPATOCYTE LYSATES.

SPLEEN(IU/IS): SPLEEN CELLS FROM RAT TOLERIZED BY INTRAUTERINE INJECTION OF HUMAN HEPATOCYTE LYSATES FOLLOWED BY INTRASPLENIC TRANSPLANTATION OF HUMAN HEPATOCYTES AFTER BIRTH.

Document - Doc ID



FIG.2



1: Molecular weight markers
2: Human serum albumin, 50 ug
3: Human serum albumin, 10 ug
4: Human serum albumin, 1 ug
5: Week 1 post-human hepatocyte transplant
6: Week 2 post-human hepatocyte transplant
7: Week 3 post-human hepatocyte transplant
8: Week 4 post-human hepatocyte transplant
9: Week 5 post-human hepatocyte transplant
10: Control animal. human fibroblast transplant. 1 week
11: Rat serum albumin, 50 ug

FIG 3

FIG.4A



FIG.4B



FIG.4C

FIG.4D



FIG.5



FIG.6A



FIG.6B

FIG.6C

FIG.6D



1: 10 ng standard human albumin
2: 10 ng standard rat albumin
3: 2 days
4: 2 weeks
5: 3 weeks
6: 5 weeks
7: 6 weeks

FIG.7

Time course of human albumin and HBV expression

Anti Human Albumin

Anti Hepatitis B Surface Antigen

1 week



FIG.8A



FIG.8B

6 weeks



FIG.8C



FIG.8D

14 weeks



FIG.8E



FIG.8F

Anti Human Albumin

Anti Hepatitis B Surface Antigen

Rat CA2

Hepatocytes
Plus HBV



FIG.9A

FIG.9B

Rat CA3

Hepatocytes
alone



FIG.9C



FIG.9D

Rat CA5

HBV alone



FIG.9E

FIG.9F

Rat CA2

minus primary Ab



FIG.9G



FIG.9H

RT-PCR Human Albuman mRNA



1: 1000 bp ladder
2: Rat RNA
3: Human RNA
4: HepG2.2.15 RNA
5: Rat CA1 - Human hepatocytes + HBV
6: Rat CA2 - Human hepatocytes + HBV
7: Rat CA3 - Human hepatocytes
8: Rat CA4 - Human hepatocytes
9: Rat CA5 - HBV
10: Rat CA6 - HBV
11: Rat CA7 - Saline

FIG 10

RT-PCR Human Albumin RNA



FIG 11A

RT-PCR HBV RNA



1: 1 kbp ladder
2: Rat liver RNA
3: Human liver RNA
4: HepG2.2.14 RNA
5: Rat CA2 - Human hepatocytes +HBV, 1 week post
6: Rat CA2 - 6 weeks post
7: Rat CA2 - 14 weeks post

FIG 11B



1: 1000 bp ladder
2: Rat RNA
3: Human RNA
4: HepG2.2.15 RNA
5: Rat CA1 – Human hepatocytes + HBV
6: Rat CA2 – Human hepatocytes + HBV
7: Rat CA3 – Human hepatocytes
8: Rat CA4 – Human hepatocytes
9: Rat CA5 – HBV
10: Rat CA6 – HBV
11: Rat CA7 – Saline

FIG.12

Hepatocytes
plus HBV

1 week



FIG.13A

Hepatocytes
plus HBV

6 weeks



FIG.13B

Hepatocytes
plus HBV

14 weeks



FIG.13C

Hepatocytes
plus HBV

1 week



FIG.14A

Hepatocytes
plus HBV

6 weeks



FIG.14B

Hepatocytes
plus HBV

14 weeks



FIG.14C


^{3}H-THYMIDINE INCORPORATION (cpm/10^6CELLS)
70000
60000
50000
40000
30000
20000
10000
0
1
2
3
4
5

FIG. 15



FIG.16A

FIG.16B



FIG.16C



FIG.16D



FIG.16E



FIG.16F

FIG.17A

FIG.17B

FIG.17C



FIG.17D



FIG.18A



FIG.18B

EP 0 694 626 B1



FIG.19A



FIG.19B


1.0
0.8
0.6
0.4
0.2
0.0
SERUM HBsAg (pg/ml)
0
10
20
30
40
50
60
70
TIME POST-INOCULATION OF HBV (DAYS)

FIG.20

T:0ST 80* TE/0E660



FIG. 21


n=4
n=13
n=13
*
*
*
350
250
150
50
Treatment/Control (%)
n=12
n=15
n=10
1
2
3
4
5
6
Intrafetal Saline
PH
Huh7
HepG2
PH
Huh7
HepG2
Responder Cell Source Treatment
Stimulator Cells
PH
Huh7
HepG2
PH
Huh7
HepG2

FIG. 22

Day 1

FIG. 23A



X125

X250

FIG. 23B

FIG. 23C



X125



X250

FIG. 23D

Day 7

FIG. 23E



X125



X250

FIG. 23F



FIG. 24A

FIG. 24B



FIG. 24C

FIG. 24D



FIG. 25

FIG. 26A

Primary human hepatocytes



FIG. 26B

palb3 plasmid



FIG. 26C

FIG. 27A



FIG. 27C





FIG. 27B



FIG. 28

Human Albumin



FIG. 29A

BrdU

Tolerized with T3 no trans-plantation

FIG. 29B

FIG. 29C



Tolerized with T3 and trans-plantation

FIG. 29D

FIG. 29E



Control no T3 no trans-plantation

FIG. 29F

PCT/US95/09528

161 nt

100 fg 10 fg 1 fg 0.1 fg 100 bp ladder

FIG. 30


Time Post-HCV Inoculation (weeks)
2
4
6
8
12
16
Huh7
+
+
+
+
+
+
HepG2
+
-
-
PHH
+
+
-
-
-
PBS
+
-
-
-
-

FIG. 31

POSTSO: TO2005060



FIG. 32